<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title xml:lang="ru">Антибиотики и Химиотерапия</journal-title><trans-title-group xml:lang="en"><trans-title>Antibiot Khimioter = Antibiotics and Chemotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0235-2990</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37489/0235-2990-2024-69-7-8-4-8</article-id><article-id custom-type="elpub" pub-id-type="custom">antibiotics-1155</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXPERIMENTAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Изучение антиклебсиеллезной активности хиназолиновых соединений с пиперазиновым циклом</article-title><trans-title-group xml:lang="en"><trans-title>Study of the Anti-klebsiella Activity of Quinazoline Compounds Containing a Piperazine Ring</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9994-4751</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Цибизова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Tsibizova</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Цибизова Александра Александровна — к. фарм. н., доцент кафедры фармакогнозии, фармацевтической технологии и биотехнологии</p><p>Астрахань</p></bio><bio xml:lang="en"><p>Alexandra A. Tsibizova — Ph. D., Associate Professor of the Department of Pharmacognosy, Pharmaceutical Technology and Biotechnology</p><p>Astrakhan</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2998-2864</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ясенявская</surname><given-names>А. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Yasenyavskaya</surname><given-names>A. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ясенявская Анна Леонидовна — к. м. н., доцент, руководитель Научно-исследовательского центра, доцент кафедры фармакогнозии, фармацевтической технологии и биотехнологии</p><p>Астрахань</p></bio><bio xml:lang="en"><p>Anna L. Yasenyavskaya — Candidate of Medical Sciences, Associate Professor, Head of the Research Center, Associate Professor of the Department of Pharmacognosy, Pharmaceutical Technology and Biotechnology</p><p>Astrakhan</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5417-4477</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Генатуллина</surname><given-names>Г. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Genatullina</surname><given-names>G. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Генатуллина Гузель Наилевна — к. б. н., заместитель руководителя Научно-исследовательского центра, доцент кафедры фармакогнозии, фармацевтической технологии и биотехнологии</p><p>Астрахань</p></bio><bio xml:lang="en"><p>Guzel N. Genatullina — Candidate of Biological Sciences, Deputy Head of the Research Center, Associate Professor of the Department of Pharmacognosy, Pharmaceutical Technology and Biotechnology</p><p>Astrakhan</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4721-0959</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Озеров</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ozerov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Озеров Александр Александрович — д. хим. н., профессор, заведующий кафедрой фармацевтической и токсикологической химии</p><p>Волгоград</p></bio><bio xml:lang="en"><p>Alexander A. Ozerov — Doctor of Chemical Sciences, Professor, Head of the Department of Pharmaceutical and Toxicological Chemistry</p><p>Volgograd</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5336-4455</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Самотруева</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Samotrueva</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Самотруева Марина Александровна — д. м. н., профессор, заведующая кафедрой фармакогнозии, фармацевтической технологии и биотехнологии</p><p>Астрахань</p></bio><bio xml:lang="en"><p>Marina A. Samotrueva — MD, Professor, Head of the Department of Pharmacognosy, Pharmaceutical Technology and Biotechnology</p><p>Astrakhan</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Астраханский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Astrakhan State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Волгоградский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Volgograd State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>20</day><month>11</month><year>2024</year></pub-date><volume>69</volume><issue>7-8</issue><fpage>4</fpage><lpage>8</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Цибизова А.А., Ясенявская А.Л., Генатуллина Г.Н., Озеров А.А., Самотруева М.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Цибизова А.А., Ясенявская А.Л., Генатуллина Г.Н., Озеров А.А., Самотруева М.А.</copyright-holder><copyright-holder xml:lang="en">Tsibizova A.A., Yasenyavskaya A.L., Genatullina G.N., Ozerov A.A., Samotrueva M.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.antibiotics-chemotherapy.ru/jour/article/view/1155">https://www.antibiotics-chemotherapy.ru/jour/article/view/1155</self-uri><abstract><p>Цель исследования — изучение противомикробной активности хиназолиновых соединений с пиперазиновым циклом в отношении Klebsiella pneumoniae. Изучение противомикробной активности проводили в условиях in vitro путем серийных разведений пиримидинового соединения с последующим определением минимальной подавляющей концентрации. Скрининг антиклебсиеллёзной активности проводили в отношении пиримидиновых производных хиназолинона с пиперазиновым циклом 1-метил-3-[2-(4-метилпиперазино)-2-оксоэтил]хиназолин-2,4(1Н,3Н)-дион (VMA–20–26), 1-метил-3-[2-(4-фенилпиперазино)-2-оксоэтил]хиназолин-2,4(1Н,3Н)-дион (VMA–20–27), 1,3-Ди[2-(4-метилпиперазин-1ил)-2-оксоэтил]хиназолин-2,4(1Н,3Н)-дион (VMA–20–29), 1,3-Ди[2-(4-фенилпиперазин-1ил)-2-оксоэтил]хиназолин-2,4(1Н,3Н)-дион (VMA–20–30), 1-Фенацин-3-[2-(4-фенилпиперазино)-2-оксоэтил]хиназолин-2,4(1Н,3Н)-дион (VMA–20–41), 1-[2-(4-фенилпиперазино-2-оксоэтил] хиназолин-2,4(1Н,3Н)-дион (VMA–24–04), синтезированных учёными Волгоградского государственного медицинского университета. Изучение противомикробной активности хиназолиновых соединений с пиперазиновым циклом в отношении K. pneumoniae установило, что наиболее активными соединениями, проявляющими бактериостатическую активность в концентрациях 1 и 0,5 мкг/мл и бактерицидную — в 4 и 16 мкг/мл, сопоставимую с ципрофлоксацином, являются 1-метил-3-[2-(4-метилпиперазино)-2-оксоэтил]хиназолин-2,4(1Н,3Н)-дион (VMA–20–26) и 1-[2-(4-фенилпиперазино-2-оксоэтил] хиназолин-2,4(1Н,3Н)-дион (VMA–24–04). Полученные результаты актуализируют проведение дальнейших детальных исследований токсичности и фармакологической активности, в том числе и противомикробной, как в условиях in vitro, так и in vivo. </p></abstract><trans-abstract xml:lang="en"><p>The aim of this study was to investigate the antimicrobial activity of piperazine ring-containing quinazoline compounds against Klebsiella pneumoniae. The study of antimicrobial activity was carried out in vitro via serial dilutions of the pyrimidine compound, with subsequent determination of the minimum inhibitory concentration. Screening for anti-Klebsiella activity was performed against pyrimidine derivatives of quinazolinone with a piperazine ring 1-methyl-3-[2-(4-methylpiperazino)-2-oxoethyl]quinazoline-2,4(1H,3H)-dione (VMA–20–26), 1-methyl-3-[2-(4-phenylpiperazino)-2-oxoethyl]quinazoline-2,4(1H,3H)-dione (VMA–20–27), 1,3-Di[2-(4-methylpiperazin-1yl)-2-oxoethyl]quinazoline-2,4(1H,3H)-dione (VMA–20–29), 1,3-Di[2-(4-phenylpiperazin-1yl)-2-oxoethyl]quinazoline-2,4(1H,3H)-dione (VMA–20–30), 1-Phenacin-3-[2-(4-phenylpiperazino)-2-oxoethyl]quinazoline-2,4(1H,3H)-dione (VMA–20–41), 1-[2-(4-phenylpiperazino-2-oxoethyl]quinazoline-2,4(1H,3H)-dione (VMA–24–04), synthesized by scientists from Volgograd State Medical University. A study of the antimicrobial activity of quinazoline compounds containing a piperazine ring against K. pneumoniae has established that the most active compounds exhibiting bacteriostatic activity at concentrations of 1 and 0.5 µg/ml and bactericidal activity at 4 and 16 µg/ml, comparable to ciproﬂoxacin, are 1-methyl-3-[2-(4-methylpiperazino)-2-oxoethyl]quinazoline-2,4(1H,3H)-dione (VMA–20–26) and 1-[2-(4-phenylpiperazino-2-oxoethyl]quinazoline-2,4(1H,3H)-dione (VMA–24–04). The obtained results prompt further detailed studies of toxicity and pharmacological activity, including antimicrobial activity, both in vitro and in vivo.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>пиримидиновые производные</kwd><kwd>хиназолиновые соединения</kwd><kwd>Klebsiella pneumoniae</kwd><kwd>бактерио- статическая активность</kwd><kwd>бактерицидная активность</kwd><kwd>противомикробная активность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>pyrimidine derivatives</kwd><kwd>quinazoline compounds</kwd><kwd>Klebsiella pneumoniae</kwd><kwd>bacteriostatic activity</kwd><kwd>bactericidal activity</kwd><kwd>antimicrobial activity</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках государственного задания Министерства здравоохранения РФ в части проведения НИР по теме «Стратегия разработки противомикробных средств, активных в отношении Klebsiella pneumoniae с множественной лекарственной устойчивостью, посредством методов молекулярного моделирования».</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Navon-Venezia S., Kondratyeva K., Carattoli A. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS microbiology reviews. 2017; 41 (3): 252–275. doi: 10.1093/femsre/fux013.</mixed-citation><mixed-citation xml:lang="en">Navon-Venezia S., Kondratyeva K., Carattoli A. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS microbiology reviews. 2017; 41 (3): 252–275. doi: 10.1093/femsre/fux013.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Wang G., Zhao G., Chao X., Xie L., Wang H. The characteristic of virulence, bioﬁlm and antibiotic resistance of Klebsiella pneumoniae. International journal of environmental research and public health. 2020; 17 (17): 6278. doi: 10.3390/ijerph17176278.</mixed-citation><mixed-citation xml:lang="en">Wang G., Zhao G., Chao X., Xie L., Wang H. The characteristic of virulence, bioﬁlm and antibiotic resistance of Klebsiella pneumoniae. International journal of environmental research and public health. 2020; 17 (17): 6278. doi: 10.3390/ijerph17176278.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Chung P. Y. The emerging problems of Klebsiella pneumoniae infections: carbapenem resistance and bioﬁlm formation. FEMS microbiology letters. 2016; 363 (20): fnw219. doi: 10.1093/femsle/fnw219.</mixed-citation><mixed-citation xml:lang="en">Chung P. Y. The emerging problems of Klebsiella pneumoniae infections: carbapenem resistance and bioﬁlm formation. FEMS microbiology letters. 2016; 363 (20): fnw219. doi: 10.1093/femsle/fnw219.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Zhuang J., Ma S. Recent development of pyrimidine‐containing antimicrobial agents. ChemMedChem. 2020; 15 (20): 1875–1886. doi: 10.1002/cmdc.202000378</mixed-citation><mixed-citation xml:lang="en">Zhuang J., Ma S. Recent development of pyrimidine‐containing antimicrobial agents. ChemMedChem. 2020; 15 (20): 1875–1886. doi: 10.1002/cmdc.202000378</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Цибизова А.А., Тюренков И.Н., Самотруева М.А., Озеров А.А., Глухова Е.Г. Оценка иммунотропных свойств нового производного пиримидина. Международный журнал прикладных и фундаментальных исследований. 2013; 11–1; 71–72.</mixed-citation><mixed-citation xml:lang="en">Tsibizova A.A., Tyurenkov I.N., Samotrueva M.A., Ozerov A.A., Glukhova E.G. Cibizova A.A., Tyurenkov I.N., Samotrueva M.A., Ozerov A.A., Gluhova E.G. Ocenka immunotropnyh svojstv novogo proizvodnogo pirimidina. Mezhdunarodnyj Zhurnal Prikladnyh I Fundamental'nyh Issledovanij. 2013; 11–1; 71–72. (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Sharma V., Chitranshi N., Agarwal A. K. Signiﬁcance and biological importance of pyrimidine in the microbial world. Int J Med Chem. 2014; (1): 202784. doi: 10.1155/2014/202784.</mixed-citation><mixed-citation xml:lang="en">Sharma V., Chitranshi N., Agarwal A. K. Signiﬁcance and biological importance of pyrimidine in the microbial world. Int J Med Chem. 2014; (1): 202784. doi: 10.1155/2014/202784.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Самотруева М.А., Цибизова А.А., Габитова Н.М., Озеров А.А., Тюренков И.Н. Противомикробная активность нового производного хиназолина VMA-13-03. Экспериментальная и клиническая фармакология. 2020; 8 (83): 24–28. doi: https://doi.org/10.30906/0869-2092-2020-83-8-24-28.</mixed-citation><mixed-citation xml:lang="en">Samotrueva M.A., Tsibizova A.A., Gabitova N.M., Ozerov A.A., Tyurenkov I.N. Protivomikrobnaya aktivnost' novogo proizvodnogo hinazolina VMA-13-03. Eksperimental'naya i Klinicheskaya Farmakologiya. 2020; 8 (83): 24–28 doi: https://doi.org/10.30906/0869-2092-2020-83-8-24-28. (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Jalageri M. D., Nagaraja A., Puttaiahgowda Y. M. Piperazine based antimicrobial polymers: a review. RSC advances. 2021; 11 (25): 15213–15230. doi: 10.1039/D1RA00341K.</mixed-citation><mixed-citation xml:lang="en">Jalageri M. D., Nagaraja A., Puttaiahgowda Y. M. Piperazine based antimicrobial polymers: a review. RSC advances. 2021; 11 (25): 15213–15230. doi: 10.1039/D1RA00341K.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Perley M., Govindarajan R. Piperazine derivatives: a review of biological activity. World Journal of Pharmaceutical Research. 2020; 9 (14): 194–204. doi: 10.20959/wjpr202014-19021.</mixed-citation><mixed-citation xml:lang="en">Perley M., Govindarajan R. Piperazine derivatives: a review of biological activity. World Journal of Pharmaceutical Research. 2020; 9 (14): 194–204. doi: 10.20959/wjpr202014-19021.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Girvase S., Dhawan S., Kumar V., Shinde S. R., Palkar M. B., Karpurmat R. Evaluation of antimicobacterial activity with the structure-activity relationship of piperazine and its analogues: A review. Eur J Med Chem. 2021; 210: 112967. doi: 10.1016/j.ejmech.2020.112967.</mixed-citation><mixed-citation xml:lang="en">Girvase S., Dhawan S., Kumar V., Shinde S. R., Palkar M. B., Karpurmat R. Evaluation of antimicobacterial activity with the structure-activity relationship of piperazine and its analogues: A review. Eur J Med Chem. 2021; 210: 112967. doi: 10.1016/j.ejmech.2020.112967.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Triveni K. S., Padmashali B., Sidash M. B., Sandeep K. Synthesis of piperazine derivatives included in pyrimidine and their antimicrobial activity. Indian Journal of Pharmaceutical Sciences. 2014; 76 (4): 332.</mixed-citation><mixed-citation xml:lang="en">Triveni K. S., Padmashali B., Sidash M. B., Sandeep K. Synthesis of piperazine derivatives included in pyrimidine and their antimicrobial activity. Indian Journal of Pharmaceutical Sciences. 2014; 76 (4): 332.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Tahir S., Mahmood T., Dastgir F., Haq I. U., Waseem A., Rashid U. Design, synthesis and anti-bacterial studies of piperazine derivatives against drug resistant bacteria. Eur J Med Chem. 2019; 166: 224–231. doi: 10.1016/j.ejmech.2019.01.062.</mixed-citation><mixed-citation xml:lang="en">Tahir S., Mahmood T., Dastgir F., Haq I. U., Waseem A., Rashid U. Design, synthesis and anti-bacterial studies of piperazine derivatives against drug resistant bacteria. Eur J Med Chem. 2019; 166: 224–231. doi: 10.1016/j.ejmech.2019.01.062.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Самотруева М.А., Старикова А.А., Башкина О.А., Цибизова А.А., Борисов А.В., Мережкина Д.В., Тюренков И.Н., Озеров А.А. Биохимические основы антимикробной активности производных хиназолинона в свете представлений об особенностях химической структуры и способах связывания с молекулами-мишенями. Обзор. Доклады Российской академии наук. Химия, науки о материалах. 2023; 1 (510): 3–27. doi: 10.31857/S2686953522600672</mixed-citation><mixed-citation xml:lang="en">Samotrueva M.A., Starikova A.A., Bashkina O.A., Tsibizova A.A., Borisov A.V., Merezhkina D.V., Tyurenkov I.N., Ozerov A.A. Biohimicheskie osnovy antimikrobnoj aktivnosti proizvodnyh hinazolinona v svete predstavlenij ob osobennostyah himicheskoj struktury i sposobah svyazyvaniya s molekulami-mishenyami. Obzor. Doklady Rossijskoj akademii nauk. Himiya, nauki o materialah. 2023; 1 (510): 3–27. doi: 10.31857/S2686953522600672 (in Russian)</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
